Annual CFI
-$4.30 M
-$77.07 M-105.90%
31 December 2023
Summary:
Rigel Pharmaceuticals annual cash flow from investing activities is currently -$4.30 million, with the most recent change of -$77.07 million (-105.90%) on 31 December 2023. During the last 3 years, it has fallen by -$51.76 million (-109.05%). RIGL annual CFI is now -105.90% below its all-time high of $72.78 million, reached on 31 December 2022.RIGL Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$3.80 M
-$7.13 M-65.21%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly cash flow from investing activities is currently $3.80 million, with the most recent change of -$7.13 million (-65.21%) on 30 September 2024. Over the past year, it has increased by +$4.97 million (+424.96%). RIGL quarterly CFI is now -89.94% below its all-time high of $37.79 million, reached on 31 March 2011.RIGL Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$8.17 M
+$4.97 M+155.47%
30 September 2024
Summary:
Rigel Pharmaceuticals TTM cash flow from investing activities is currently $8.17 million, with the most recent change of +$4.97 million (+155.47%) on 30 September 2024. Over the past year, it has dropped by -$13.01 million (-61.42%). RIGL TTM CFI is now -90.62% below its all-time high of $87.07 million, reached on 30 September 2012.RIGL TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -105.9% | +425.0% | -61.4% |
| 3 y3 years | -109.0% | +108.6% | +110.5% |
| 5 y5 years | -117.2% | +1393.2% | +158.6% |
RIGL Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -105.9% | +94.6% | -83.2% | +108.6% | -88.8% | +110.2% |
| 5 y | 5 years | -105.9% | +94.6% | -84.5% | +107.7% | -88.8% | +110.2% |
| alltime | all time | -105.9% | +94.6% | -89.9% | +103.5% | -90.6% | +107.8% |
Rigel Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.80 M(-65.2%) | $8.17 M(+155.5%) |
| June 2024 | - | $10.93 M(+3391.7%) | $3.20 M(-167.2%) |
| Mar 2024 | - | $313.00 K(-104.6%) | -$4.76 M(+10.8%) |
| Dec 2023 | -$4.30 M(-105.9%) | -$6.87 M(+487.5%) | -$4.30 M(-120.3%) |
| Sept 2023 | - | -$1.17 M(-139.4%) | $21.18 M(-35.4%) |
| June 2023 | - | $2.97 M(+282.2%) | $32.80 M(-35.6%) |
| Mar 2023 | - | $777.00 K(-95.8%) | $50.92 M(-30.0%) |
| Dec 2022 | $72.78 M(-190.9%) | $18.60 M(+77.9%) | $72.78 M(+20.0%) |
| Sept 2022 | - | $10.46 M(-50.4%) | $60.67 M(+943.3%) |
| June 2022 | - | $21.09 M(-6.8%) | $5.82 M(-109.0%) |
| Mar 2022 | - | $22.63 M(+248.8%) | -$64.94 M(-18.9%) |
| Dec 2021 | -$80.04 M(-268.6%) | $6.49 M(-114.6%) | -$80.04 M(+2.9%) |
| Sept 2021 | - | -$44.40 M(-10.6%) | -$77.81 M(+460.3%) |
| June 2021 | - | -$49.66 M(-759.3%) | -$13.89 M(-145.5%) |
| Mar 2021 | - | $7.53 M(-13.5%) | $30.54 M(-35.7%) |
| Dec 2020 | $47.47 M(-300.7%) | $8.71 M(-55.4%) | $47.47 M(+52.4%) |
| Sept 2020 | - | $19.53 M(-473.1%) | $31.14 M(+175.2%) |
| June 2020 | - | -$5.23 M(-121.4%) | $11.32 M(+502.6%) |
| Mar 2020 | - | $24.46 M(-421.1%) | $1.88 M(-107.9%) |
| Dec 2019 | -$23.66 M(-194.8%) | -$7.62 M(+2490.8%) | -$23.66 M(+69.6%) |
| Sept 2019 | - | -$294.00 K(-98.0%) | -$13.95 M(-733.0%) |
| June 2019 | - | -$14.67 M(+1267.4%) | $2.20 M(+227.3%) |
| Mar 2019 | - | -$1.07 M(-151.3%) | $673.00 K(-97.3%) |
| Dec 2018 | $24.96 M(-228.2%) | $2.09 M(-86.8%) | $24.96 M(-301.8%) |
| Sept 2018 | - | $15.86 M(-197.9%) | -$12.37 M(-40.1%) |
| June 2018 | - | -$16.20 M(-169.8%) | -$20.66 M(-630.5%) |
| Mar 2018 | - | $23.22 M(-165.9%) | $3.90 M(-120.0%) |
| Dec 2017 | -$19.47 M(-178.3%) | -$35.24 M(-566.1%) | -$19.47 M(-208.9%) |
| Sept 2017 | - | $7.56 M(-9.5%) | $17.88 M(-13.7%) |
| June 2017 | - | $8.36 M(-5670.7%) | $20.71 M(-34.3%) |
| Mar 2017 | - | -$150.00 K(-107.1%) | $31.50 M(+26.6%) |
| Dec 2016 | $24.88 M(-44.2%) | $2.11 M(-79.7%) | $24.88 M(-30.0%) |
| Sept 2016 | - | $10.39 M(-45.7%) | $35.52 M(-36.3%) |
| June 2016 | - | $19.15 M(-382.8%) | $55.77 M(+96.9%) |
| Mar 2016 | - | -$6.77 M(-153.1%) | $28.33 M(-36.5%) |
| Dec 2015 | $44.61 M(-29.1%) | $12.75 M(-58.4%) | $44.61 M(-8.5%) |
| Sept 2015 | - | $30.65 M(-469.5%) | $48.78 M(+91.8%) |
| June 2015 | - | -$8.29 M(-187.2%) | $25.43 M(-59.0%) |
| Mar 2015 | - | $9.51 M(-43.8%) | $61.98 M(-1.5%) |
| Dec 2014 | $62.93 M(-13.1%) | $16.91 M(+131.6%) | $62.93 M(-9.5%) |
| Sept 2014 | - | $7.30 M(-74.1%) | $69.52 M(-9.9%) |
| June 2014 | - | $28.25 M(+170.1%) | $77.12 M(+35.1%) |
| Mar 2014 | - | $10.46 M(-55.5%) | $57.07 M(-21.2%) |
| Dec 2013 | $72.40 M(-285.5%) | $23.50 M(+57.6%) | $72.40 M(-221.9%) |
| Sept 2013 | - | $14.91 M(+81.6%) | -$59.37 M(+7.6%) |
| June 2013 | - | $8.21 M(-68.2%) | -$55.20 M(+40.0%) |
| Mar 2013 | - | $25.79 M(-123.8%) | -$39.43 M(+1.0%) |
| Dec 2012 | -$39.03 M | -$108.27 M(-667.5%) | -$39.03 M(-144.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $19.08 M(-20.4%) | $87.07 M(+54.1%) |
| June 2012 | - | $23.97 M(-8.4%) | $56.50 M(-175.9%) |
| Mar 2012 | - | $26.18 M(+46.8%) | -$74.45 M(+18.5%) |
| Dec 2011 | -$62.85 M(+17.7%) | $17.84 M(-255.1%) | -$62.85 M(-39.9%) |
| Sept 2011 | - | -$11.50 M(-89.3%) | -$104.64 M(+24.2%) |
| June 2011 | - | -$106.98 M(-383.1%) | -$84.27 M(+112.7%) |
| Mar 2011 | - | $37.79 M(-257.8%) | -$39.61 M(-25.8%) |
| Dec 2010 | -$53.40 M(+74.2%) | -$23.95 M(-370.0%) | -$53.40 M(-38.5%) |
| Sept 2010 | - | $8.87 M(-114.2%) | -$86.78 M(-13.8%) |
| June 2010 | - | -$62.32 M(-359.7%) | -$100.67 M(+275.8%) |
| Mar 2010 | - | $24.00 M(-141.9%) | -$26.79 M(-12.6%) |
| Dec 2009 | -$30.66 M(+13.7%) | -$57.33 M(+1042.3%) | -$30.66 M(-175.7%) |
| Sept 2009 | - | -$5.02 M(-143.4%) | $40.51 M(-48.2%) |
| June 2009 | - | $11.56 M(-42.6%) | $78.27 M(+115.2%) |
| Mar 2009 | - | $20.12 M(+45.3%) | $36.38 M(-234.9%) |
| Dec 2008 | -$26.97 M(+246.1%) | $13.85 M(-57.7%) | -$26.97 M(-12.6%) |
| Sept 2008 | - | $32.74 M(-207.9%) | -$30.86 M(-60.2%) |
| June 2008 | - | -$30.33 M(-29.8%) | -$77.46 M(+25.2%) |
| Mar 2008 | - | -$43.23 M(-534.2%) | -$61.87 M(+694.0%) |
| Dec 2007 | -$7.79 M(-297.4%) | $9.96 M(-171.8%) | -$7.79 M(-48.1%) |
| Sept 2007 | - | -$13.86 M(-6.0%) | -$15.03 M(+1950.2%) |
| June 2007 | - | -$14.74 M(-235.8%) | -$733.00 K(-104.3%) |
| Mar 2007 | - | $10.86 M(+298.9%) | $16.86 M(+327.1%) |
| Dec 2006 | $3.95 M(-283.5%) | $2.72 M(+524.1%) | $3.95 M(-115.6%) |
| Sept 2006 | - | $436.00 K(-84.7%) | -$25.30 M(+109.5%) |
| June 2006 | - | $2.85 M(-238.4%) | -$12.08 M(+70.8%) |
| Mar 2006 | - | -$2.06 M(-92.2%) | -$7.07 M(+228.8%) |
| Dec 2005 | -$2.15 M(-91.7%) | -$26.53 M(-294.2%) | -$2.15 M(-107.5%) |
| Sept 2005 | - | $13.66 M(+73.9%) | $28.74 M(+24.0%) |
| June 2005 | - | $7.86 M(+174.3%) | $23.19 M(-386.1%) |
| Mar 2005 | - | $2.86 M(-34.4%) | -$8.11 M(-68.6%) |
| Dec 2004 | -$25.80 M(-30.8%) | $4.37 M(-46.1%) | -$25.80 M(-25.2%) |
| Sept 2004 | - | $8.10 M(-134.6%) | -$34.48 M(-54.3%) |
| June 2004 | - | -$23.44 M(+58.0%) | -$75.42 M(+46.0%) |
| Mar 2004 | - | -$14.84 M(+244.4%) | -$51.66 M(+38.5%) |
| Dec 2003 | -$37.31 M(-291.4%) | -$4.31 M(-86.9%) | -$37.31 M(+36.9%) |
| Sept 2003 | - | -$32.84 M(<-9900.0%) | -$27.25 M(-202.6%) |
| June 2003 | - | $329.00 K(-167.8%) | $26.55 M(-1.4%) |
| Mar 2003 | - | -$485.00 K(-108.4%) | $26.92 M(+38.1%) |
| Dec 2002 | $19.49 M(-192.2%) | $5.75 M(-72.5%) | $19.49 M(+12.1%) |
| Sept 2002 | - | $20.95 M(+2875.9%) | $17.39 M(+297.0%) |
| June 2002 | - | $704.00 K(-108.9%) | $4.38 M(-168.8%) |
| Mar 2002 | - | -$7.92 M(-317.0%) | -$6.36 M(-69.9%) |
| Dec 2001 | -$21.15 M(+179.1%) | $3.65 M(-54.1%) | -$21.15 M(-14.7%) |
| Sept 2001 | - | $7.94 M(-179.1%) | -$24.80 M(-24.3%) |
| June 2001 | - | -$10.04 M(-55.8%) | -$32.74 M(+44.2%) |
| Mar 2001 | - | -$22.70 M | -$22.70 M |
| Dec 2000 | -$7.58 M(+7.0%) | - | - |
| Dec 1999 | -$7.09 M | - | - |
FAQ
- What is Rigel Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual CFI year-on-year change?
- What is Rigel Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly CFI year-on-year change?
- What is Rigel Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals TTM CFI year-on-year change?
What is Rigel Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of RIGL is -$4.30 M
What is the all time high annual CFI for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual cash flow from investing activities is $72.78 M
What is Rigel Pharmaceuticals annual CFI year-on-year change?
Over the past year, RIGL annual cash flow from investing activities has changed by -$77.07 M (-105.90%)
What is Rigel Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of RIGL is $3.80 M
What is the all time high quarterly CFI for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly cash flow from investing activities is $37.79 M
What is Rigel Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, RIGL quarterly cash flow from investing activities has changed by +$4.97 M (+424.96%)
What is Rigel Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of RIGL is $8.17 M
What is the all time high TTM CFI for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high TTM cash flow from investing activities is $87.07 M
What is Rigel Pharmaceuticals TTM CFI year-on-year change?
Over the past year, RIGL TTM cash flow from investing activities has changed by -$13.01 M (-61.42%)